The primary objective of this multimodal positron emission tomography (PET) study is to use PET brain imaging to measure both MOR (Mu-Opioid receptors) and KOR (kappa-opioid receptors) in participants with alcohol use disorder (AUD) and to quantify the relationships between MOR and KOR, separately and jointly, to key clinical outcomes (e.g., craving, mood, withdrawal, time to lapse) during a quit attempt.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Regional binding availability and volume of distribution of (Mu-Opioid receptors)
Timeframe: Within first 6 days of abstinence
Regional binding availability and volume of distribution of (Mu-Opioid receptors)
Timeframe: Between 3 to 6 weeks into alcohol cessation
Regional binding availability and volume of distribution of (Kappa-Opioid receptors)
Timeframe: Within first 6 days of abstinence
Regional binding availability and volume of distribution of (Kappa-Opioid receptors)
Timeframe: Between 3 to 6 weeks into alcohol cessation
Alcohol Cue Reactivity Craving
Timeframe: Within first 6 days of abstinence
Change in Alcohol Withdrawal
Timeframe: Up to 1 month prior to initial imaging and up to 6 days into alcohol cessation
Change in Alcohol Use
Timeframe: Up to 1 month prior to initial imaging and up to 6 days into alcohol cessation
Change in Alcohol Craving
Timeframe: Up to 1 month prior to initial imaging and up to 6 days into alcohol cessation
Change in Mood
Timeframe: Up to 1 month prior to initial imaging and up to 6 days into alcohol cessation